Natural killer cells are attractive as cancer immunotherapy agents because — unlike T cells — they evade immune rejection and do not induce cytokine storms. But capturing their activity in effective therapies remains a work in progress.
This is a preview of subscription content, log in via an institution to check access.
Change history
13 March 2023
In the version of this article initially published, there were errors in the sentence now reading “Innate Pharma’s collaboration with Sanofi on an NK cell engager platform was recently strengthened by the big pharma’s in-licensing of a preclinical multi-specific NK cell engager targeting the immune checkpoint B7H3 and the activating NK cell receptors CD16a and NKp46,” which replaces “Innate Pharma’s collaboration with Sanofi on an NK cell engager platform was recently strengthened by the big pharma’s in-licensing of a preclinical trispecific NK cell engager targeting the immune checkpoint B3-H7 and the inhibitory NK cell receptors CD16a and NKp46,” while in the text now reading “From a single unit of cord blood, it can generate about 8,000 doses, each containing 1 billion cryopreserved NK cells,” “8,000” replaces “80,000.” The changes have been made in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sheridan, C. Industry appetite for natural killer cells intensifies. Nat Biotechnol 41, 159–161 (2023). https://doi.org/10.1038/s41587-023-01671-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-023-01671-5
- Springer Nature America, Inc.
This article is cited by
-
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies
Journal of Hematology & Oncology (2023)